Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

2.010 +0.060 (+3.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Price and Volume

Volume	842,451
Open	1.970
Bid (Size)	1.910 (800)
Ask (Size)	2.010 (100)
Prev. Close	1.950
Today's Range	1.960 - 2.159
52wk Range	1.330 - 3.470
Shares Outstanding	31,056,238
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Thursday's after hours session: top gainers and losers ↗

December 25, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Which stocks are moving after the closing bell on Wednesday? ↗

December 24, 2025

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Performance

YTD	+3.1%	+3.1%
1 Month	+39.6%	+39.6%
3 Month	+24.1%	+24.1%
6 Month	+4.1%	+4.1%
1 Year	-36.4%	-36.4%

More News

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

November 20, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 20, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 20, 2025

Via Benzinga

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

November 20, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

November 14, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

August 19, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 18, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

August 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 18, 2025

Via Benzinga

Inhibikase Posts Wider Loss in Q2 ↗

August 14, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 27, 2025

Via Benzinga

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

April 14, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

March 27, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Announces Expansion of Senior Leadership Team

February 24, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

February 18, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

February 12, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 30, 2025

Via Chartmill

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

January 29, 2025

Via Chartmill

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

November 14, 2024

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 08, 2024

Via Benzinga

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 08, 2024

Via Benzinga

Frequently Asked Questions

Is Inhibikase Therapeutics, Inc. - Common Stock publicly traded?

Yes, Inhibikase Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Inhibikase Therapeutics, Inc. - Common Stock trade on?

Inhibikase Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock?

The ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock is IKT on the Nasdaq Stock Market

What is the current price of Inhibikase Therapeutics, Inc. - Common Stock?

The current price of Inhibikase Therapeutics, Inc. - Common Stock is 2.010

When was Inhibikase Therapeutics, Inc. - Common Stock last traded?

The last trade of Inhibikase Therapeutics, Inc. - Common Stock was at 01/05/26 04:00 PM ET

What is the market capitalization of Inhibikase Therapeutics, Inc. - Common Stock?

The market capitalization of Inhibikase Therapeutics, Inc. - Common Stock is 62.42M

How many shares of Inhibikase Therapeutics, Inc. - Common Stock are outstanding?

Inhibikase Therapeutics, Inc. - Common Stock has 62M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.